PubMed Health⌕ Search

Biomedical subjects

P H Konits

Publications and source records attributed to P H Konits.

6 recordsLinked to original sources

Serum thyroid hormone changes during whole body hyperthermia.

In order to elucidate changes in thyroid hormone metabolism during acute heat stress, we measured sequentially serum thyroxine (T4), triiothyronine (T3), and reverse T3 (rT3) levels in 5 patients with neoplasia during treatment with whole body hyperthermia. The core temperature was raised from 37.0 degrees C to 42.0 degrees C over a 2-hour period, maintained at 42.0 degrees C for 2 hours, and then cooled to 37.0 degrees C over 2 hours. This short period of severe hyperthermia produced a fivefold rise in rT3 and a fall in T3 levels to one half of baseline levels. T4 and free T4 levels increased slightly, but thyrotropin (measured in two patients) did not change. These changes in T3 and rT3 levels were detectable at the fourth hour after onset of hyperthermia, were maximal at 24 and 48 hours, and in one patient were uncorrected after 4 days. We conclude that this reciprocal change in T3 and rT3 levels is a response to stress and may represent in part adaptation to a high environmental temperature by the suppression of theromengic T3. Whole body hyperthermia of short duration for cancer therapy produces profound changes in the peripheral degradation of thyroxine, which last for several days. This must be considered in the management of patients receiving hyperthermia, and the technique itself may prove to be a useful model for the study of adaptation to heat stress.

Humans↗

Possible pulmonary toxicity secondary to vinblastine.

A number of chemotherapeutic agents and multiple other drugs are known to produce interstitial pneumonitis and pulmonary fibrosis. It is important to realize which agents can produce or interact with other drugs to produce this complication. Two patients receiving combination chemotherapy with mitomycin-C and vinblastine developed diffuse interstitial pulmonary infiltrates in temporal relationship to vinblastine administration. The infiltrates cleared but recurred and produced chronic pulmonary changes. Since it is likely that the vinblastine either caused or contributed to the pulmonary damage, this drug must be considered among the antineoplastic agents which can cause or contribute to interstitial pulmonary disease.

Adenocarcinoma↗

Lung cancer as a complication of prolonged survival in patients with lymphoma.

As a result of successful therapy with radiation, chemotherapy, or both, patients with lymphoma are living longer. The improved survival has led to an increased awareness of long term complications including second or subsequent malignancies. We have recently seen six cases of lung cancer--three adenocarcinomas, one squamous cell carcinoma, and two small cell carcinomas--among 655 patients with Hodgkin and non-Hodgkin lymphoma suggesting a possible association, although other carcinogenic or cocarcinogenic factors cannot be eliminated.

Adenocarcinoma↗

Doxorubicin plus VP-16-213 for the treatment of refractory breast carcinoma.

Thirty patients with refractory advanced breast cancer who had no prior treatment with doxorubicin or VP-16-213 received doxorubicin 45 mg/m2 I.V. on day 1 and VP-16-213 50 mg/m2 I.V. on days 1 through 5. Courses were repeated every 21 days when hematologic recovery permitted. Among 30 evaluable patients, one had a complete response and 11 had a partial response. Four patients had stabilization of their disease. There was thus a 40% response rate with a median response duration of 146 days (range 35-540). Toxicity included moderate to severe myelosuppression, infections, hemorrhage, and mucositis. In these poor prognoses in previously treated patients, the combination of doxorubicin and VP-16-213 appears to be an effective secondary treatment for metastatic breast cancer.

Adult↗

Mitomycin C and vinblastine chemotherapy for advanced breast cancer.

Mitomycin C, 20 mg/m2 day 1, and vinblastine, 0.15 mg/m2 days 1 and 21, were administered intravenously to 31 patients with refractory previously treated advanced breast cancer. Courses were repeated every six to eight weeks when adequate hematologic recovery permitted. Thirty of the 31 patients were evaluable; one had a complete response and 11 had a partial response. Four patients had stabilization of their disease. There was a 12/30 (40%) response rate with a median response duration of 127 days (range 69--412 days). Toxicity included moderate to severe myelosuppression, infections, hemorrhage, neurologic symptoms, pulmonary toxicity and mucositis. In previously treated patients with poor prognoses, the combination of mitomycin C and vinblastine appears to be a worthwhile secondary treatment for metastatic breast cancer.

Adult↗